XML 37 R14.htm IDEA: XBRL DOCUMENT
v3.25.4

Intangible assets | 12 Months Ended
--- | ---
Dec. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible assets | Intangible assets Intangible Assets Intangible assets consisted of the following:
| December 31, 2024 |  | December 31, 2025
| Gross carrying amount |  | Accumulated amortization |  | Net book value |  | Gross carrying amount |  | Accumulated amortization |  | Net book value
License | $ | 38,433 |  |  | $ | 29,111 |  |  | $ | 9,322 |  |  | $ | 16,620 |  |  | $ | 8,968 |  |  | $ | 7,652 |
Technology | 52,700 |  |  | 19,909 |  |  | 32,791 |  |  | 52,700 |  |  | 21,971 |  |  | 30,729 |
| $ | 91,133 |  |  | $ | 49,020 |  |  | $ | 42,113 |  |  | $ | 69,320 |  |  | $ | 30,939 |  |  | $ | 38,381 |
Amortization expense related to intangible assets for the years ended December 31, 2023, 2024 and 2025 was $11.6 million, $14.3 million and $3.7 million, respectively. For the year ended December 31, 2024, the Company recorded a full impairment charge of the carrying value of $32.0 million (or $23.3 million, net of deferred income tax) associated with the IPR&D acquired through the 2021 acquisition of TetraGenetics and a full impairment charge of the carrying value of $32.0 million (or $23.3 million, net of deferred income tax) associated with the IPR&D acquired through the 2020 acquisition of Trianni. Details of a corresponding impact reducing the contingent consideration associated with the TetraGenetics acquisition are disclosed in Note 15. The impairment charges were due to our ongoing internal program prioritization which also resulted in the discontinuance of the development of next-generation transgenic mice. Depreciation and amortization expense and impairment charges are reflected within depreciation, amortization, and impairment expense on the consolidated statements of loss and comprehensive loss. Amortization expense on intangible assets subject to amortization is estimated to be as follows for each of the next five years ended December 31:
| Amortization Expense
2026 | $ | 3,732 |
2027 | 3,732 |
2028 | 3,732 |
2029 | 3,732 |
2030 | 2,632 |
| $ | 17,560 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration